Skip to content
Operation Infinite Justice – Lifestyle
Author:
MBX Biosciences, Inc.
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
March 9, 2026
←
Previous Page
1
2